Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP General Counsel and Secret | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,373 |
Ending reported balance
After 2026-08-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-19 · Exercise / conversion · Acquired 12,282 · Balance 45,392 Row 2 · 2026-08-19 · Tax withholding · Disposed 9,019 · Balance 36,373 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 12,283 |
Reported balance
After 2026-08-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-19 · Exercise / conversion · Disposed 12,282 · Balance 12,283 F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 3,402 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,402 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 5,407 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,407 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 413 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 413 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date November 17, 2003 · Filed November 18, 2003
Section 16 reporting ended · disclosed 2003-11-18. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 218 | $689.43 | $150,295.74 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,688 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 218 shares of Company stock on April 1, 2022 at prices ranging from $689.07 to $689.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 799 | $688.59 | $550,183.41 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 4 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,906 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 799 shares of Company stock on April 1, 2022 at prices ranging from $688.05 to $688.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 497 | $687.41 | $341,642.77 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,705 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 497 shares of Company stock on April 1, 2022 at prices ranging from $687.12 to $687.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 557 | $686.26 | $382,246.82 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,202 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 557 shares of Company stock on April 1, 2022 at prices ranging from $686.15 to $686.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 369 | $685.71 | $253,026.99 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,759 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 369 shares of Company stock on April 1, 2022 at prices ranging from $685.49 to $685.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| December 11, 2021 Filed Dec 14, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 697 | $664.34 | $463,044.98 |
DisclosureSEC source: 0001708138-21-000103 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,051 Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001883850-21-000023 · edgardoc.xml · derivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 19,772 | $657.11 | $12,992,378.92 |
DisclosureSEC source: 0001883850-21-000023 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,748 Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 30,000 | $179.13 | $5,373,900.00 |
DisclosureSEC source: 0001883850-21-000023 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,253 | $0.00 Strike: $644.54 | $0.00 |
DisclosureSEC source: 0001883850-21-000023 · edgardoc.xml · derivative · entry 7 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,253 Underlying: Common Stock · 14,253 shares Expires 2031-12-08 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-21-000023 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,520 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2023 and 50% on December 8, 2025. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $666.22 | $666.22 |
DisclosureSEC source: 0001237899-21-000018 · edgardoc.xml · nonDerivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,182 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 41 | $665.40 | $27,281.40 |
DisclosureSEC source: 0001237899-21-000018 · edgardoc.xml · nonDerivative · entry 4 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,183 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 41 shares of Company stock on August 23, 2021 at prices ranging from $665.21 to $665.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,383 | $661.80 | $2,238,869.40 |
DisclosureSEC source: 0001237899-21-000018 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,224 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001237899-21-000018 · edgardoc.xml · derivative · entry 8 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,575 | $664.85 | $4,371,388.75 |
DisclosureSEC source: 0001237899-21-000018 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,607 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $179.13 | $1,791,300.00 |
DisclosureSEC source: 0001237899-21-000018 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,398 | $580.00 | $1,970,840.00 |
DisclosureSEC source: 0001708138-21-000036 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,182 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001708138-21-000036 · edgardoc.xml · derivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,602 | $582.20 | $3,843,684.40 |
DisclosureSEC source: 0001708138-21-000036 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,580 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $179.13 | $1,791,300.00 |
DisclosureSEC source: 0001708138-21-000036 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,950 | $0.00 Strike: $492.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000050 · edgardoc.xml · derivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,950 Underlying: Common Stock · 19,950 shares Expires 2030-12-09 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000050 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,368 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 9, 2022 and 50% on December 9, 2024. Read SEC document |
| August 31, 2020 Filed Aug 31, 2020 20:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,672 | $615.04 | $2,873,466.88 |
DisclosureSEC source: 0001237899-20-000039 · edgardoc.xml · nonDerivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,438 F1 · price: Represents volume-weighted average price of sales of 4,672 shares of Company stock on August 31, 2020 at prices ranging from $615.00 to $615.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-20-000039 · edgardoc.xml · derivative · entry 8 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: With respect to 6,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 4,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-20-000039 · edgardoc.xml · derivative · entry 7 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 6,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: With respect to 6,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 4,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,131 | $614.87 | $1,310,287.97 |
DisclosureSEC source: 0001237899-20-000039 · edgardoc.xml · nonDerivative · entry 4 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,110 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,000 | $52.03 | $208,120.00 |
DisclosureSEC source: 0001237899-20-000039 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,197 | $614.87 | $1,965,739.39 |
DisclosureSEC source: 0001237899-20-000039 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,241 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 6,000 | $52.03 | $312,180.00 |
DisclosureSEC source: 0001237899-20-000039 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 15, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,380 | $572.00 | $4,793,360.00 |
DisclosureSEC source: 0001237899-20-000020 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,438 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 18,311 | $0.00 Strike: $59.20 | $0.00 |
DisclosureSEC source: 0001237899-20-000020 · edgardoc.xml · derivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,311 shares Expires 2021-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 9,931 | $573.18 | $5,692,250.58 |
DisclosureSEC source: 0001237899-20-000020 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,818 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 18,311 | $59.20 | $1,084,011.20 |
DisclosureSEC source: 0001237899-20-000020 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 577 | $573.59 | $330,961.43 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · nonDerivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,438 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 577 shares of Company stock on April 20, 2020 at prices ranging from $573.31 to $573.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 61 | $572.94 | $34,949.34 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · nonDerivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,015 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 112 | $571.65 | $64,024.80 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · nonDerivative · entry 4 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,076 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 125 | $570.27 | $71,283.75 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,188 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 125 shares of Company stock on April 20, 2020 at prices ranging from $570.03 to $570.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 234 | $569.41 | $133,241.94 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,313 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 234 shares of Company stock on April 20, 2020 at prices ranging from $569.22 to $569.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 669 | $567.30 | $379,523.70 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,547 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 669 shares of Company stock on April 20, 2020 at prices ranging from $567.00 to $567.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,189 | $566.44 | $673,497.16 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 30 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,216 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 1,189 shares of Company stock on April 20, 2020 at prices ranging from $566.00 to $566.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. F13 · balance_after: Form one of two Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,468 | $565.60 | $830,300.80 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 29 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,405 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 1,468 shares of Company stock on April 20, 2020 at prices ranging from $565.03 to $565.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 377 | $564.74 | $212,906.98 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 28 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,873 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 377 shares of Company stock on April 20, 2020 at prices ranging from $564.03 to $564.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 416 | $563.58 | $234,449.28 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 27 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,250 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 416 shares of Company stock on April 20, 2020 at prices ranging from $563.35 to $563.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 21 | $562.71 | $11,816.91 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 26 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,666 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 51 | $561.57 | $28,640.07 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 25 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,687 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $59.20 | $0.00 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · derivative · entry 10 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,311 Underlying: Common Stock · 5,000 shares Expires 2021-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. F7 · balance_after: Form two of two Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,622 | $0.00 Strike: $59.20 | $0.00 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · derivative · entry 9 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,311 Underlying: Common Stock · 6,622 shares Expires 2021-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,720 | $555.82 | $1,511,830.40 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 24 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,738 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $59.20 | $296,000.00 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 23 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.